Abstracts tagged "pregnancy"

Abstract Number: 2414 • 2018 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score in Women with Systemic Lupus Erythematosus and Adverse Pregnancy Outcomes
Karen Schreiber¹, Massimo Radin², Irene Cecchi³, Elena Rubini⁴, Dario Roccatello⁵, Søren Jacobsen⁶, Maria Jose Cuadrado⁷ and Savino Sciascia⁸, ¹Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶University of Copenhagen, Copenhagen, Denmark, ⁷Clinica Universidad de Navarra, Madrid, Spain, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) are associated with pregnancy complications. Methods: 143 women ever pregnant with SLE who presented in our…
Abstract Number: 2421 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Women with Rheumatic Diseases and Thrombophilia Treated in a Multidisciplinary Unit
Isabel Añón Oñate¹, Irene Notario¹, Miguel Ángel Ferrer¹, Lorena Pérez¹, María Ramírez¹ and Rafael Cáliz², ¹Rheumatology, Hospital Universitario Virgen de las Nieves, Granada, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain
Background/Purpose: To evaluate the efficacy of the treatment on the pregnancy outcomes of women with Rheumatic Diseases and Thrombophilia from a Spanish cohort. Their pregnancies…
Abstract Number: 2426 • 2018 ACR/ARHP Annual Meeting
Defining a Standardized Core Data Set for Pregnancy Registers in Rheumatic Diseases – an European Approach
Yvette Meißner¹, Anja Strangfeld¹, Nathalie Costedoat-Chalumeau^2,3, Frauke Förger^4,5, Anna Moltó⁶, Marianne Wallenius^7,8 and Rebecca Fischer-Betz⁹, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Université Paris-Descartes, Paris, France, ³Internal Medicine, Hopital Cochin, Paris, France, ⁴University of Bern, Bern, Switzerland, ⁵Rheumatology, Clinical Immunology and Allergology, Inselspital-University Hospital, Bern, Switzerland, ⁶Rheumatology B Department, Paris Descartes University, Cochin Hospital, AP-HP,Paris, Paris, France, ⁷Norwegian University of Science and Technology, Trondheim, Norway, ⁸St. Olav's University Hospital, Trondheim, Norway, ⁹Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany
Background/Purpose: Robust data on the outcomes of pregnancy and influence of drug exposure in various inflammatory rheumatic diseases (IRD) are needed. Joint analyses of data…
Abstract Number: 2427 • 2018 ACR/ARHP Annual Meeting
Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series
Marianna Meroni¹, Maria De Santis², Elena Generali², Angela Ceribelli³, Marta Caprioli³, Giacomo Maria Guidelli², Natasa Isailovic², Gaetano Maria Fara⁴, Carlo Selmi² and Maurizio Cutolo⁵, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁴Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy
Background/Purpose: Certolizumab pegol (CTZ) is a TNFα inhibitor indicated for the treatment of women affected by rheumatoid arthritis (RA) throughout the whole pregnancy. Some concern,…
Abstract Number: 5 • 2017 ACR/ARHP Annual Meeting
Clinical Utility of the Global Antiphospholipid Syndrome Score (GAPSS) for Risk Stratification: A Pooled Analysisfrom 2273 Patients
Savino Sciascia¹, Massimo Radin², Giovanni Sanna³, Irene Cecchi⁴, Dario Roccatello⁵ and Maria Laura Bertolaccini⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, London, United Kingdom, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Academic Department of Vascular Surgery, Cardiovascular Division, King's College London, United Kingdom, London, United Kingdom
Background/Purpose: Recently, our group conceived a risk score for clinical manifestations of APS [the global APS score or GAPSS] that takes into account the combination…
Abstract Number: 1295 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcome in Patients with SLE Compared to Patients with Other Inflammatory Rheumatic Diseases: Real World Data from a Prospective Pregnancy Register
Rebecca Fischer-Betz¹, Christina Bungartz², Matthias Schneider¹, Jutta Richter¹, Anja Weiss², Angela Zink³ and Anja Strangfeld⁴, ¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany, ⁴Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: SLE pregnancies are complicated due to risk for maternal disease exacerbation and potential for fetal and neonatal complications. With careful pre-pregnancy counseling and monitoring…
Abstract Number: 1299 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Nathaniel Harris¹, Amanda M. Eudy² and Megan E. B. Clowse², ¹Duke University School of Medicine, Durham, NC, ²Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is…
Abstract Number: 1309 • 2017 ACR/ARHP Annual Meeting
Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database
Megan E. B. Clowse¹, Angela E. Scheuerle², Christina D Chambers³, Anita Afzali⁴, Alexa Kimball⁵, John J. Cush⁶, Maureen Cooney⁷, Laura Shaughnessy⁷, Mark Vanderkelen⁸ and Frauke Förger⁹, ¹Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, ²UT Southwestern Medical Center, Dallas, TX, ³UC San Diego School of Medicine, San Diego, CA, ⁴University of Washington Harborview Medical Center, Seattle, WA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Baylor Scott & White Research Institute, Dallas, TX, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Braine-l’Alleud, Belgium, ⁹Inselspital, University of Bern, Bern, Switzerland
Background/Purpose: Anti-tumor necrosis factor medications (anti-TNFs) are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently,…
Abstract Number: 1812 • 2017 ACR/ARHP Annual Meeting
Preeclampsia and Incident Cardiovascular Disease in SLE Pregnancy
Julia F Simard¹, Marios Rossides², Elizabeth V. Arkema³, Elisabet Svenungsson⁴, Anna-Karin Wikstrom⁵, Murray Mittleman⁶ and Jane E. Salmon⁷, ¹Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA, ²Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁶Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, ⁷Medicine/Rheumatology, Hospital of Special Surgery, New York, NY
Background/Purpose: Pre-pregnancy cardiovascular health has been associated with preeclampsia during pregnancy, as well as future cardiovascular disease (CVD). Preeclampsia is related to endothelial dysfunction, hypertension,…
Abstract Number: 1957 • 2017 ACR/ARHP Annual Meeting
Impact of Maternal Systemic Autoimmune Rheumatic Diseases on Neonatal Outcomes: A Population-Level Analysis
Stephanie Keeling¹, Anamaria Savu² and Padmaja Kaul³, ¹Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada, ²Canadian Vigour Center, Edmonton, AB, Canada, ³Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The impact of systemic autoimmune rheumatic diseases (SARDS) on peripartum outcomes is not well described at a population level despite the potential for active…
Abstract Number: 2439 • 2016 ACR/ARHP Annual Meeting
Effect of Pregnancy Counseling on the Outcome of Pregnancies in Women with Systemic Lupus Erythematosus: A Prospective Observational Study
Rebecca Fischer-Betz¹, Lisa Kueppers², Ralph Brinks², Oliver Sander³, Christof Specker⁴ and Matthias Schneider³, ¹Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine University, Duesseldorf, Duesseldorf, Germany, ²Department of Rheumatology&Hiller Research Unit, Heinrich-Heine-University, Duesseldorf, Germany, ³Department of Rheumatology & Hiller Research Unit, Heinrich-Heine-University, Duesseldorf, Germany, ⁴Rheumatology and Clinical Immunology, Kliniken Essen Sued, Essen, Germany
Background/Purpose: Pregnancies in women with systemic lupus erythematosus (SLE) are associated with increased frequencies of adverse pregnancy outcomes (APOs). Preconception counseling including risk stratification and…
Abstract Number: 2440 • 2016 ACR/ARHP Annual Meeting
First Results from the Prospective German Pregnancy Register
Rebecca Fischer-Betz¹, Christina Bungartz², Jutta Richter¹, Angela Zink³, Matthias Schneider¹, Anja Weiss², Joachim Listing⁴ and Anja Strangfeld⁵, ¹Department of Rheumatology & Hiller Research Unit, Heinrich-Heine-University, Duesseldorf, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Epidemiology Unit, German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ⁴German Rheumatism Research Center, Berlin, Germany, ⁵Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: There is limited evidence on the safety of treatment during pregnancy and lactation. With the increasing number of new therapeutic options for inflammatory rheumatic…
Abstract Number: 2442 • 2016 ACR/ARHP Annual Meeting
Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis
Neda Amiri¹, Gretchen Bandoli², Diana L Johnson² and Christina D. Chambers², ¹Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, University of California, San Diego, La Jolla, CA
Use of Nonsteroidal Anti-inflammatory Drugs in Pregnant Women with Inflammatory Arthritis Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are generally contraindicated in the third trimester of pregnancy…
Abstract Number: 2443 • 2016 ACR/ARHP Annual Meeting
Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study
Neda Amiri¹, Gretchen Bandoli² and Christina Chambers², ¹Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, University of California, San Diego, La Jolla, CA
Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study Background/Purpose: While there is some evidence that women with psoriasis (Pso) and…
Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Mark Berman¹, Daphna Paran¹, Yonatan Wolman¹ and Ori Elkayam², ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].